LUNG CANCER

December 13, 2021

Risks Associated With Concomitant Radiotherapy and Immune Checkpoint Inhibitors

December 13, 2021

Study Reveals EGFR Positivity Poor Predictor of Recurrence in NSCLC

December 13, 2021

Chemotherapy Added to Immunotherapy Improves Survival in NSCLC Patients

November 8, 2021

FDA Approves Atezolizumab for Adjuvant Treatment of Stage II-IIIA NSCLC

November 8, 2021

Lung Cancer-Associated Fibroblasts May Be Instrumental in Personalized Treatments

November 8, 2021

Studying Safety & Efficacy of Immune Checkpoint Inhibitors in Relapsed SCLC

October 8, 2021

Fam-Trastuzumab Deruxtecan-Nxki Promising Against HER2-Mutated NSCLC

October 8, 2021

Disparities in Lung Cancer-Screening Eligibility Persist

October 8, 2021

FDA Approves First Oral Therapy for EGFR Exon20 Insertion+ NSCLC

September 22, 2021

FDA Grants Priority Review to Atezolizumab for Early Non-Small Cell Lung Cancer

September 22, 2021

Lung Cancer Screening Rates Mostly Unchanged During Pandemic

September 22, 2021

Cemiplimab Considerably Improved Overall Survival in Patients With Advanced NSCLC

August 12, 2021

No Clinical Benefit From Ipilimumab Plus Nivolumab in Squamous NSCLC

September 2022

September 2022

In This Issue Digital Magazine Archives Subscription

Copyright © 2000 - 2022 Jobson Medical Information LLC unless otherwise noted. All rights reserved. Reproduction in whole or in part without permission is prohibited.